logo BDSP

Base documentaire

  1. Prevention and treatment recommendations for respiratory syncytial virus infection : Background and clinical experience 40 years after discovery.

    Article - En anglais

    Though 40 years have passed since its discovery, respiratory syncytial virus (RSV), one of the most ubiquitous viruses known, continues to evade most of our efforts to prevent or treat the clinical disease it causes.

    Long recognised as the most common cause of lower respiratory tract infections in virtually all children in the first 2 years of life, it has been increasingly recognised as a cause of more serious disease in several'high risk'populations.

    These populations include infants with cardiac or pulmonary disease and infants and adults with immuno-deficiencies, particularly those undergoing bone marrow transplantation.

    Early attempts to immunise children with a simple formalin-inactivated vaccine led to severe disease in vaccinated children who subsequently were infected with RSV from the community.

    Other vaccine constructs have failed for a variety of reasons, although surface glycoprotein subunit vaccines may hold promise.

    For years, ribavirin, a synthetic nucleoside analogue administered by constant aerosol, has been felt by many to lead to more rapid improvement in clinical disease caused by RSV, but it is still unclear whether its benefits are truly significant. (...)

    Mots-clés Pascal : Virose, Infection, Virus syncytial humain, Spumavirinae, Retroviridae, Virus, Pneumopathie, Homme, Prévention, Chimiothérapie, Immunothérapie, Traitement, Epidémiologie, Pathogénie, Article synthèse, Vaccin, Ribavirine, IgG, Triazole dérivé, Appareil respiratoire pathologie, Poumon pathologie, Anticorps monoclonal, Corticostéroïde, Antiviral

    Mots-clés Pascal anglais : Viral disease, Infection, Human syncytial virus, Spumavirinae, Retroviridae, Virus, Pneumopathy, Human, Prevention, Chemotherapy, Immunotherapy, Treatment, Epidemiology, Pathogenesis, Review, Vaccine, Ribavirin, IgG, Triazole derivatives, Respiratory disease, Lung disease, Monoclonal antibody, Corticosteroid, Antiviral

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0056982

    Code Inist : 002B02S05. Création : 14/05/1998.